Anthony Letai
Auto-generated profile, based on publicly available information

Anthony Letai

Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2019 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
RSRumani Singh
Rumani Singh
ALAnthony Letai
Anthony Letai
Kristopher SarosiekKristopher Sarosiek
Kristopher Sarosiek

3 January 2019 in Blood
Verified
Journal Article
Open access
PDF file
CDCourtney D. DiNardo
Courtney D. DiNardo
KPKeith Pratz
Keith Pratz
VPVinod Pullarkat
Vinod Pullarkat
BJBrian A Jonas
Brian A Jonas
MAMartha Arellano
Martha Arellano
ALAnthony Letai
Anthony Letai
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance. We report safety and efficacy of venetoclax with decitabine or azacitidine from a large, multicenter, phase 1b dose-escalation and expansion study. Patients (N = 145) were at least 65 years old with treatment-naive AML and were ineligible for intensive chemotherapy. During dose escalation, oral venetoclax was administered at 400, 800, or 1200 mg daily in combination with either decitabine (20 mg/m2, days 1-5, intravenously [IV]) or azacitidine (75 mg/m2, days 1-7, IV or subcutaneously). In the expansion, 400 or 800 mg venetoclax with either hypomethylating agent (HMA) was given. Median age was 74 years, with poor-risk cytogenetics in 49% of patients. Common adverse events (>30%) included nausea, diarrhea, constipation, febrile neutropenia, fatigue, hypokalemia, decreased appetite, and decreased white blood cell count. No tumor lysis syndrome was observed. With a median time on study of 8.9 months, 67% of patients (all doses) achieved complete remission (CR) + CR with incomplete count recovery (CRi), with a CR + CRi rate of 73% in the venetoclax 400 mg + HMA cohort. Patients with poor-risk cytogenetics and those at least 75 years old had CR + CRi rates of 60% and 65%, respectively. The median duration of CR + CRi (all patients) was 11.3 months, and median overall survival (mOS) was 17.5 months; mOS has not been reached for the 400-mg venetoclax cohort. The novel combination of venetoclax with decitabine or azacitidine was effective and well tolerated in elderly patients with AML (This trial was registered at www.clinicaltrials.gov as #NCT02203773).

1 October 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MKMarina Konopleva
Marina Konopleva
DPDaniel A. Pollyea
Daniel A. Pollyea
JPJalaja Potluri
Jalaja Potluri
BCBrenda Chyla
Brenda Chyla
LHLeah Hogdal
Leah Hogdal
ALAnthony Letai
Anthony Letai
We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy. Responses were evaluated following revised International Working Group (IWG) criteria. The overall response rate was 19%; an additional 19% of patients demonstrated antileukemic activity not meeting IWG criteria (partial bone marrow response and incomplete hematologic recovery). Twelve (38%) patients had isocitrate dehydrogenase 1/2 mutations, of whom 4 (33%) achieved complete response or complete response with incomplete blood count recovery. Six (19%) patients had BCL2-sensitive protein index at screening, which correlated with time on study. BH3 profiling was consistent with on-target BCL2 inhibition and identified potential resistance mechanisms. Common adverse events included nausea, diarrhea and vomiting (all grades), and febrile neutropenia and hypokalemia (grade 3/4). Venetoclax demonstrated activity and acceptable tolerability in patients with AML and adverse features. Significance: Venetoclax monotherapy demonstrated clinical activity in patients with AML (relapsed/refractory or unfit for intensive chemotherapy) with a tolerable safety profile in this phase II study. Predictive markers of response consistent with BCL2 dependence were identified. Clinical and preclinical findings provide a compelling rationale to evaluate venetoclax combined with other agents in AML. Cancer Discov; 6(10); 1106–17. ©2016 AACR. See related commentary by Pullarkat and Newman, p. 1082. This article is highlighted in the In This Issue feature, p. 1069

15 February 2009 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
JBJoslyn K. Brunelle
Joslyn K. Brunelle
ALAnthony Letai
Anthony Letai

1 March 2014 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
RPRongqing Pan
Rongqing Pan
LHLeah J. Hogdal
Leah J. Hogdal
JBJuliana M. Benito
Juliana M. Benito
DBDonna Bucci
Donna Bucci
LHLina Han
Lina Han
ALAnthony G. Letai
Anthony G. Letai
B-cell leukemia/lymphoma 2 (BCL-2) prevents commitment to programmed cell death at the mitochondrion. It remains a challenge to identify those tumors that are best treated by inhibition of BCL-2. Here, we demonstrate that acute myeloid leukemia (AML) cell lines, primary patient samples, and murine primary xenografts are very sensitive to treatment with the selective BCL-2 antagonist ABT-199. In primary patient cells, the median IC50 was approximately 10 nmol/L, and cell death occurred within 2 hours. Our ex vivo sensitivity results compare favorably with those observed for chronic lymphocytic leukemia, a disease for which ABT-199 has demonstrated consistent activity in clinical trials. Moreover, mitochondrial studies using BH3 profiling demonstrate activity at the mitochondrion that correlates well with cytotoxicity, supporting an on-target mitochondrial mechanism of action. Our protein and BH3 profiling studies provide promising tools that can be tested as predictive biomarkers in any clinical trial of ABT-199 in AML. Significance: Although targeting BCL-2 has largely been investigated in lymphoid cancers, we present preclinical results of targeting BCL-2 in AML. These results support clinical testing of the small-molecule BCL-2 antagonist ABT-199 in AML, accompanied by testing of predictive biomarkers used in this study. Cancer Discov; 4(3); 362–75. ©2013 AACR. See related commentary by Hockenbery, p. 278 This article is highlighted in the In This Issue feature, p. 259

25 November 2011 in Science
Verified
Journal Article
Closed access
PDF file
TCTriona Ni Chonghaile
Triona Ni Chonghaile
Kristopher SarosiekKristopher Sarosiek
Kristopher Sarosiek
TVThanh-Trang Vo
Thanh-Trang Vo
JRJeremy A. Ryan
Jeremy A. Ryan
ATAnupama Tammareddi
Anupama Tammareddi
ALAnthony Letai
Anthony Letai
The mitochondrial state of a tumor cell prior to chemotherapy may help determine how well it responds to drug treatment.